Clinical trial Recruiting at 1 site Observational Ages 65 and up

Digital and Plasma Biomarkers for Delirium in the ICU

Official title: Delirium Evaluation With Longitudinal Tau Assessment

Run by Scripps Health · NCT07694206 · Data updated 2026-11-12

This study tests whether digital biomarkers and blood biomarkers can help detect and predict delirium in older adults in the ICU.

More Critical Illness trials

Quick facts

Study typeObservational
Ages65 Years and up
SexAll
Enrollment100 (estimated)
SponsorScripps Health
Academic / other
Locations2 sites (La Jolla, California and 1 other locations)
StatusRecruiting
StartedMay 28, 2026
Main results expectedOctober 30, 2027
Study endsDecember 31, 2027
Registry record updatedJuly 9, 2026
Trial IDNCT07694206 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Older adults admitted to the ICU who can consent or have a legally authorized representative and are expected to stay at least 48 hours, English-speaking.

Probably not a fit

Patients with advanced dementia, end-stage liver disease on replacement therapy, undergoing renal replacement therapy, or with structural brain injuries may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study monitors older ICU patients to see if wearable digital data and plasma biomarkers relate to delirium. Participants will wear a device to continuously collect biometric information and provide serial blood samples during their ICU stay, with daily delirium assessments by study staff. The goal is to see if these biomarkers can help detect, predict, or prognosticate delirium in the ICU setting. The study is conducted at Scripps Health facilities and recruits adults admitted to the ICU who can consent or have a representative consent. It excludes patients with advanced dementia, liver failure requiring replacement therapy, renal replacement therapy, or significant structural brain injuries.

Why it matters

Potential benefit: If successful, the findings could lead to earlier delirium detection and better risk stratification in ICU patients.

How similar studies have gone: Previous research has explored biomarkers and sleep metrics in delirium, but combining digital biometrics with plasma biomarkers in ICU delirium is a relatively novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Admitted to the intensive care unit
* Able to consent or have a legally authorized representative consent on their behalf
* English speaker
* Expected ICU stay of 48 hours or more

Exclusion Criteria:

* Advanced dementia
* End stage liver disease
* Renal replacement therapy
* Structural brain injury, including but not limited to traumatic brain injury, cerebrovascular accident and intracranial hemorrhage,

Where it's running

  • Scripps Memorial La Jolla Hospital
    San Diego, California, United States
    Recruiting
  • Scripps Green Hospital
    La Jolla, California, United States
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.